{
    "root": "2f20d43e-a477-a839-e063-6394a90ace38",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Methotrexate",
    "value": "20250227",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "METHOTREXATE SODIUM",
            "code": "3IG1E710ZN"
        }
    ],
    "indications": "methotrexate tablets dihydrofolate reductase inhibitor indicated : treatment adults pediatric patients acute lymphoblastic leukemia ( ) part combination chemotherapy maintenance regimen ( 1.1 ) treatment adults mycosis fungoides ( 1.1 ) treatment adults relapsed refractory non-hodgkin lymphoma part metronomic combination regimen ( 1.1 ) treatment adults rheumatoid arthritis ( 1.2 ) treatment pediatric patients polyarticular juvenile idiopathic arthritis ( pjia ) ( 1.3 ) treatment adults severe psoriasis ( 1.4 )",
    "contraindications": "instruct patients caregivers take recommended directed , medication errors led deaths . ( 2.1 , 5.9 ) verify pregnancy status females reproductive potential starting methotrexate tablets ( 4 , 5.1 ) . : recommended 20 mg/m 2 orally weekly part combination chemotherapy maintenance regimen . ( 2.2 ) mycosis fungoides : recommended 25 mg 75 mg orally weekly monotherapy ; 10 mg/m 2 orally twice weekly part combination chemotherapy . ( 2.2 ) relapsed refractory non-hodgkin lymphoma : recommended 2.5 mg orally two four times per week part metronomic combination chemotherapy . ( 2.2 ) rheumatoid arthritis : recommended starting 7.5 mg orally weekly ; adjust dose achieve optimal response ( 2.3 ) pjia : recommended starting 10 mg/m 2 orally weekly ; adjust dose achieve optimal response ( 2.4 ) psoriasis : recommended 10 mg 25 mg orally weekly adequate response achieved . ( 2.5 )",
    "warningsAndPrecautions": "methotrexate tablets , usp contain amount 2.5 mg methotrexate equivalent 2.74 mg methotrexate sodium pale yellow yellow , round shaped , biconvex , uncoated tablets , debossed one side hz ” “ 1 ” either side score line plain side . 36 count bottle child-resistant closure ndc 16729-486-36 100 count bottle child-resistant closure ndc 16729-486-01 dispense tight , light-resistant container defined usp , child-resistant closure . store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . methotrexate tablets cytotoxic . follow applicable special handling disposal procedures . 1",
    "adverseReactions": "contraindicated : methotrexate tablets contraindicated : pregnant women receiving methotrexate tablets treatment non-neoplastic diseases [ ( 5.1 ) , ( 8.1 , 8.3 ) ] . patients history severe hypersensitivity , including anaphylaxis , methotrexate . [ ( 5.2 ) ] .",
    "indications_original": "Methotrexate tablets is a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 )",
    "contraindications_original": "Instruct patients and caregivers to take the recommended dosage as directed, because medication errors have led to deaths. ( 2.1 , 5.9 ) Verify pregnancy status in females of reproductive potential before starting Methotrexate Tablets ( 4 , 5.1 ). ALL: The recommended dosage is 20 mg/m 2 orally once weekly as a part of a combination chemotherapy maintenance regimen. ( 2.2 ) Mycosis fungoides: The recommended dosage is 25 mg to 75 mg orally once weekly as monotherapy; 10 mg/m 2 orally twice weekly as part of combination chemotherapy. ( 2.2 ) Relapsed or refractory non-Hodgkin lymphoma: The recommended dosage is 2.5 mg orally two to four times per week as part of metronomic combination chemotherapy. ( 2.2 ) Rheumatoid Arthritis: The recommended starting dosage is 7.5 mg orally once weekly; adjust dose to achieve an optimal response ( 2.3 ) pJIA: The recommended starting dosage is 10 mg/m 2 orally once weekly; adjust dose to achieve an optimal response ( 2.4 ) Psoriasis: The recommended dosage is 10 mg to 25 mg orally once weekly until adequate response is achieved. ( 2.5 )",
    "warningsAndPrecautions_original": "Methotrexate Tablets, USP contain an amount of 2.5 mg of methotrexate equivalent to 2.74 mg methotrexate sodium and are pale yellow to yellow, round shaped, biconvex, uncoated tablets, debossed on one side HZ” and “1” on either side of the score line and plain on other side. \n  \n                     \n                  \n                  36 count bottle with a child-resistant closure                                          NDC 16729-486-36\n                  100 count bottle with a child-resistant closure                                        NDC 16729-486-01 \n  \n                     \n                  \n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure.\n                  \n                     Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].\n                  \n                  Methotrexate Tablets is a cytotoxic drug. Follow applicable special handling and disposal procedures.\n \n  1",
    "adverseReactions_original": "is contraindicated in: Methotrexate Tablets is contraindicated in:\n                  \n                  \n                     Pregnant women receiving Methotrexate Tablets for treatment of non-neoplastic diseases\n  \n   [see Warnings and Precautions (\n   \n    5.1), and Use in Specific Populations (\n   \n    8.1,\n   \n    8.3)].\n  \n   \n                     \n                     Patients with a history of a severe hypersensitivity reactions, including anaphylaxis, to methotrexate.\n  \n   [see Warnings and Precautions (\n   \n    5.2)]."
}